10-Q: Prelude Therapeutics Reports Q1 2025 Financial Results and Provides Business Update

Prelude Therapeutics reports a net loss of $32.1 million for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern without additional funding.

Summary

• Prelude Therapeutics Incorporated reported its financial results for the quarter ended March 31, 2025.
• The company is a clinical-stage precision oncology company focused on developing novel cancer medicines.
• For Q1 2025, Prelude Therapeutics reported a net loss of $32.1 million, compared to a net loss of $31.4 million for the same period in 2024.
• Research and development expenses increased to $28.8 million from $27.4 million year-over-year, primarily due to increased expenses related to SMARCA2 clinical trials.
• General and administrative expenses decreased to $5.8 million from $6.9 million year-over-year, mainly due to a decrease in non-cash stock-based compensation expense.
• As of March 31, 2025, the company had cash, cash equivalents, restricted cash, and marketable securities totaling $103.1 million.
• The company believes that its current cash resources will not be sufficient to fund operating expenses and capital expenditure requirements for at least the next twelve months without additional funding, raising substantial doubt about its ability to continue as a going concern.
• The company plans to seek additional funding through public or private equity offerings, debt financings, collaborations, strategic alliances, and licensing arrangements.
• Prelude received a Nasdaq delisting notice on March 27, 2025, due to not meeting the minimum bid price requirement of $1.00 per share.
• The company has until September 23, 2025, to regain compliance.
• The company is advancing its SMARCA2 degrader programs, PRT3789 and PRT7732, with data updates expected in the second half of 2025.
• The company is also developing precision antibody drug conjugates (ADCs) and KAT6A degraders.
• Prelude intends to seek a partner for the continued advancement of its CDK9 candidate, PRT2527.

Sentiment

Score: 3

Explanation: The sentiment is low due to the significant net loss, the going concern warning, and the Nasdaq delisting notice. While there are positive aspects related to the clinical pipeline, the financial instability overshadows them.

Positives

• The company is actively progressing its SMARCA2 degrader programs, PRT3789 and PRT7732, with clinical trials underway and data updates expected in the second half of 2025.
• Prelude has a diverse pipeline consisting of multiple distinct programs including kinases, targeted protein degraders, and precision antibody drug conjugates.
• The company is collaborating with Merck on a Phase 2 clinical trial evaluating PRT3789 in combination with KEYTRUDA in patients with SMARCA4-mutated cancers.
• Prelude has identified a series of potent, selective and orally bioavailable SMARCA2 degraders.
• The company is open to partnering for the development of its KAT6A degrader program, indicating potential for external validation and funding.
• The company is seeking a partner for the continued advancement of its CDK9 candidate, PRT2527, allowing them to focus on their SMARCA2 degrader development program.

Negatives

• The company reported a net loss of $32.1 million for Q1 2025.
• Prelude Therapeutics expresses substantial doubt about its ability to continue as a going concern without additional funding.
• The company received a Nasdaq delisting notice due to not meeting the minimum bid price requirement.
• The company has no product revenue to date and does not expect to generate any revenue in the foreseeable future.
• The company's cash, cash equivalents, restricted cash, and marketable securities totaled $103.1 million as of March 31, 2025, which may not be sufficient to fund operations for the next twelve months.
• The company's ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of its current or future product candidates.

Risks

• The company's financial statements contain a statement regarding a substantial doubt about the company's ability to continue as a going concern.
• The company faces risks and uncertainties regarding product development, limited working capital, recurring losses, negative cash flow from operations, and the ability to obtain future capital.
• Failure to comply with Nasdaq's continued listing requirements could result in delisting, affecting the stock's market price and liquidity and reducing the ability to raise capital.
• The company's ability to continue as a going concern is dependent on its ability to obtain the necessary financing to meet its obligations.
• The company's dependence on third-party manufacturing organizations and third-party collaboration and licensing agreements poses risks.
• The company's lack of sales and marketing activities poses risks.
• The company's ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of its current or future product candidates.

Future Outlook

The company expects to continue incurring significant expenses and operating losses for the foreseeable future as it advances its product candidates through development and clinical trials. They plan to seek additional funding through various means, including equity offerings, debt financings, collaborations, and strategic alliances.

Management Comments

• The document does not contain direct quotes from management, but it does state the company's belief that its approach could result in better targeted cancer therapies.
• Management believes that selective SMARCA2 degrader has the potential to be of benefit in up to 10% of non-small cell lung cancer patients in the United States including many other tumor types with the SMARCA4 mutation.

Industry Context

Prelude Therapeutics operates in the competitive biotechnology industry, focusing on precision oncology. The company's SMARCA2 degrader programs target a specific subset of cancer patients with SMARCA4 mutations, which represents a targeted approach within the broader oncology market. The development of precision ADCs and KAT6A degraders further diversifies their pipeline and addresses different mechanisms of cancer.

Comparison to Industry Standards

• It's difficult to directly compare Prelude's results to industry standards without knowing the specific stage and focus of comparable companies.
• However, early-stage biotech companies often experience significant net losses as they invest heavily in research and development.
• Companies like Relay Therapeutics and Black Diamond Therapeutics are also focused on precision oncology and targeted therapies, but their specific financial situations and clinical programs may differ.
• The Nasdaq delisting notice is a concern, as it can impact investor confidence and the company's ability to raise capital, similar to what other companies facing delisting threats experience.
• The company's cash runway and need for additional funding are common challenges for biotech companies in the clinical development stage.

Legal Proceedings

• The company may be involved in legal proceedings arising in the ordinary course of its business and may receive letters alleging infringement of patents or other intellectual property rights.

Stakeholder Impact

• Shareholders face the risk of stock dilution if the company raises additional capital through equity offerings.
• Employees may be affected by potential delays, reductions, or terminations of research and development programs if the company is unable to obtain funding.
• The company's ability to develop and commercialize product candidates could impact patients with high unmet medical needs.
• The company's financial instability could affect its relationships with suppliers, CROs, and other partners.

Next Steps

• The company intends to monitor the closing bid price of the common stock and consider its available options to resolve the noncompliance with the Minimum Bid Price Requirement.
• The company expects to file a prospectus supplement to the 2024 Shelf Registration Statement in order to continue to allow us to access the Sales Agreement.
• The company expects to provide an initial first-in-human data update at a major medical meeting in the second half of 2025.
• The company is advancing its SMARCA2 degrader programs, PRT3789 and PRT7732, with data updates expected in the second half of 2025.
• The company is also developing precision antibody drug conjugates (ADCs) and KAT6A degraders.
• Prelude intends to seek a partner for the continued advancement of its CDK9 candidate, PRT2527.

Key Dates

Keywords

SMARCA2 degrader, oncology, clinical trials, PRT3789, PRT7732, precision medicine, biotechnology, financial results, going concern, Nasdaq, delisting, funding, research and development, net loss, liquidity